ROCKVILLE, Md., June 14 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointments of John W. Madsen, Ph.D., as Head of Process and Manufacturing Operations and Steven Pincus, Ph.D., as Head of Analytical and Quality Operations. Dr. Madsen joined Novavax in 2008 as Director of BioProcess Development with responsibility for development of Novavax's seasonal and pandemic influenza vaccines for clinical testing. Dr. Pincus joined Novavax in 2007 as Director of Analytical Development with responsibility for product validation in support of preclinical and clinical studies. They will report to Novavax's CEO, Rahul Singhvi, Sc.D.
"John and Steve are uniquely well-qualified to manage our manufacturing process development, and quality organizations," said Dr. Singhvi. "Under their guidance and support, we have scaled up VLP vaccine manufacturing in large-scale stirred tank bioreactors, doubled our vaccine production capacity in our pilot manufacturing facility, substantially reduced manufacturing costs and advanced plans to commercialize our vaccine candidates. These achievements reflect their leadership skills, as well as the talent and dedication of their teams, and will be critical to our future success."
Previously, Dr. Madsen was Director of Manufacturing for the Vaccine Clinical Materials Program at SAIC-Frederick, Inc., where he was responsible for clinical trials materials manufacturing, and Director of Pharmaceutical Science at Entremed, Inc., where he was responsible for production, technology transfer and scale-up. Before joining Novavax, Dr. Pincus was Senio
|SOURCE Novavax, Inc.|
Copyright©2010 PR Newswire.
All rights reserved